A standard daily multivitamin slowed biological aging by roughly four months over two years in a clinical trial of 958 older adults, according to findings published in Nature Medicine in May 2026. The results come from the COSMOS trial, a large randomized study led by researchers at Brigham and Women’s Hospital, and they represent some of the strongest evidence to date that a common, inexpensive supplement can produce measurable changes in how cells age at the molecular level.
For the tens of millions of older Americans who already pop a daily multivitamin, the study raises a question that has lingered for decades: does that pill actually do something meaningful, or is it just expensive urine? This trial offers a partial, and genuinely surprising, answer.
What the COSMOS trial found
COSMOS, short for the COcoa Supplement and Multivitamin Outcomes Study, originally enrolled more than 21,000 U.S. adults, with women aged 65 and older and men aged 60 and older. The full trial used a 2×2 factorial design, randomizing participants to receive a daily multivitamin (Centrum Silver), a cocoa extract supplement, both, or placebos. The epigenetic aging analysis focused on a subset of 958 participants whose blood samples were collected and analyzed for DNA methylation patterns at baseline and after two years.
DNA methylation is a chemical modification that accumulates on genes over a lifetime. Scientists have developed algorithms called epigenetic clocks that read these methylation patterns across hundreds of thousands of genomic sites to estimate a person’s biological age, which can diverge significantly from their age in calendar years. Someone who is 70 might have the methylation profile of a 65-year-old or a 75-year-old, depending on genetics, lifestyle, and environmental exposures.
In the COSMOS subset, participants who took the daily multivitamin showed a biological aging rate approximately four months slower than those on placebo over the two-year period. The cocoa extract arm did not produce a comparable effect, which isolates the signal to the multivitamin itself.
One subgroup finding stood out. Participants whose biological age already exceeded their calendar age by a wider margin at the start of the trial appeared to benefit more from the supplement. In other words, people who were aging fastest at the cellular level seemed to get the biggest nudge in the other direction. The researchers had planned this subgroup analysis before the trial began, which lends it more credibility than a post-hoc data dive, though it still needs confirmation in a dedicated follow-up study.
Why this matters, and why it’s limited
Randomized, placebo-controlled trials testing supplements against biological aging markers are rare. Most anti-aging supplement claims rest on animal studies, observational data, or small uncontrolled experiments. COSMOS is notable because it was large, rigorously designed, and prespecified its epigenetic analysis, meaning the researchers committed to examining these outcomes before they saw any results. That design choice sharply reduces the risk of cherry-picking favorable data.
Still, four months of slowed biological aging is a modest effect, and several important caveats apply.
The 958-person epigenetic subset is a fraction of the full COSMOS cohort. Whether the effect holds across people with different health profiles, dietary patterns, or racial and ethnic backgrounds has not been established. The study population skewed toward older, predominantly white adults, which limits how broadly the findings can be applied.
The biological mechanism remains unclear. A multivitamin contains dozens of micronutrients, and the published analysis does not identify which ones drove the epigenetic changes. It is plausible that the benefit reflects correction of subclinical nutrient deficiencies common in older adults rather than a direct anti-aging effect. Without baseline nutrient-level data for the epigenetic subset, that question stays open.
The follow-up period was two years. Biological aging unfolds over decades, and there is no data yet on whether the four-month benefit accumulates with continued use, levels off, or disappears once the supplement is stopped. The COSMOS team has indicated that additional analyses are underway, but no longer-term epigenetic results have been released.
Perhaps most importantly, epigenetic clocks are surrogate markers. They correlate with real-world health outcomes like mortality risk and chronic disease incidence, but they are not themselves clinical endpoints. A four-month shift in biological age might translate into fewer heart attacks or a longer life, or it might not. COSMOS was originally designed to track hard outcomes such as cardiovascular events and cancer, and those results will ultimately carry more weight for clinical decision-making than a molecular biomarker alone.
Putting the effect size in perspective
Four months may not sound like much, but context matters. Established lifestyle interventions like regular exercise, smoking cessation, and maintaining a healthy weight have larger documented effects on biological aging and lifespan. A 2022 design paper for COSMOS, published in Contemporary Clinical Trials, laid out the trial’s rationale partly on the basis that even small, population-wide effects from an inexpensive intervention could have outsized public health impact simply because so many people already take multivitamins.
That logic has some force. A prescription drug that slowed aging by four months in a randomized trial would generate enormous pharmaceutical interest. The fact that the intervention here costs a few cents per day and is already sitting in millions of medicine cabinets makes the finding practically significant even if the effect size is small by clinical-trial standards.
But it also means the finding is easy to overinterpret. A multivitamin is not a longevity drug. It does not replace exercise, good nutrition, sleep, or medical management of conditions like hypertension and diabetes. Those factors have far larger and better-documented effects on healthspan than any single pill.
What to do with this information
For older adults already taking a daily multivitamin, this study offers some reassurance that the habit may carry a measurable, if modest, biological benefit. For those not currently taking one, the results are intriguing but not yet strong enough to constitute a blanket recommendation.
Several practical points are worth noting. The trial used a specific formulation, Centrum Silver, in a specific age group. The results do not automatically extend to younger adults, different supplement brands, or high-dose “anti-aging” stacks marketed online. People taking multiple medications or managing complex health conditions should talk to a clinician before adding any supplement, even one sold over the counter. Multivitamins can interact with certain drugs and may contribute to excessive intake of specific nutrients when combined with fortified foods.
Where the science goes from here
This research arrives at a moment when the science of aging is shifting rapidly. Epigenetic clocks, once confined to academic labs, are moving toward potential clinical use as tools for measuring how fast a person is aging and whether interventions are working. Large randomized trials like COSMOS are beginning to test whether affordable, widely available interventions can move those clocks in a favorable direction.
The multivitamin signal from COSMOS is an early data point, not a final verdict. Independent replication in a separate trial population would strengthen the case considerably. So would mechanistic studies identifying which nutrients are responsible and whether baseline deficiency status predicts who benefits most. The COSMOS investigators have signaled that further analyses are coming, and the aging-research community will be watching closely.
For now, the most honest reading is this: in a well-designed trial of older adults, a cheap daily multivitamin produced a small but real shift in a validated marker of biological aging, with hints that the people aging fastest may benefit the most. It is not a fountain of youth. But it is one of the few randomized results in a field crowded with hype, and that alone makes it worth paying attention to.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
